140 related articles for article (PubMed ID: 32021096)
1. Metabolic Stability Assessment of Larotrectinib Using Liquid Chromatography Tandem Mass Spectrometry.
Attwa MW; Kadi AA; Darwish HW
Drug Des Devel Ther; 2020; 14():111-119. PubMed ID: 32021096
[TBL] [Abstract][Full Text] [Related]
2. LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes.
Mostafa GAE; Kadi AA; AlMasoud N; Attwa MW; Al-Shakliah NS; AlRabiah H
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Aug; 1179():122806. PubMed ID: 34325312
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies.
Attwa MW; Kadi AA; Abdelhameed AS; Alhazmi HA
Drug Des Devel Ther; 2020; 14():783-793. PubMed ID: 32158196
[TBL] [Abstract][Full Text] [Related]
4. LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation.
Attwa MW; Abdelhameed AS; Kadi AA
Drug Des Devel Ther; 2021; 15():3915-3925. PubMed ID: 34552321
[TBL] [Abstract][Full Text] [Related]
5. Assessment of In Silico and In Vitro Selpercatinib Metabolic Stability in Human Liver Microsomes Using a Validated LC-MS/MS Method.
Attwa MW; AlRabiah H; Mostafa GAE; Bakheit AH; Kadi AA
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985590
[TBL] [Abstract][Full Text] [Related]
6. LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay.
Attwa MW; Abdelhameed AS; Al-Shakliah NS; Kadi AA
Drug Des Devel Ther; 2020; 14():4439-4449. PubMed ID: 33122888
[TBL] [Abstract][Full Text] [Related]
7. Development and Validation of a Rapid LC-MS/MS Method for Quantifying Alvocidib: In Silico and In Vitro Metabolic Stability Estimation in Human Liver Microsomes.
Attwa MW; AlRabiah H; Kadi AA
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903615
[TBL] [Abstract][Full Text] [Related]
8. Development of an LC-MS/MS Method for Quantification of Sapitinib in Human Liver Microsomes: In Silico and In Vitro Metabolic Stability Evaluation.
Attwa MW; AlRabiah H; Mostafa GAE; Kadi AA
Molecules; 2023 Mar; 28(5):. PubMed ID: 36903565
[TBL] [Abstract][Full Text] [Related]
9. Estimation of zorifertinib metabolic stability in human liver microsomes using LC-MS/MS.
Attwa MW; Al-Shakliah NS; AlRabiah H; Kadi AA; Abdelhameed AS
J Pharm Biomed Anal; 2022 Mar; 211():114626. PubMed ID: 35123331
[TBL] [Abstract][Full Text] [Related]
10. Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes for the estimation of its in vitro hepatic intrinsic clearance.
Tang LWT; Chan ECY
J Pharm Biomed Anal; 2022 May; 214():114731. PubMed ID: 35325798
[TBL] [Abstract][Full Text] [Related]
11. Validated HPLC Method for Quantification of a Novel Trk Inhibitor, Larotrectinib in Mice Plasma: Application to a Pharmacokinetic Study.
Tripathy HK; Nair Manju SV; Zakkula A; Bestha RM; Dittakavi S; Mullangi R
Drug Res (Stuttg); 2020 Feb; 70(2-03):101-106. PubMed ID: 31931548
[TBL] [Abstract][Full Text] [Related]
12. A highly sensitive LC-MS/MS method to determine novel Bruton's tyrosine kinase inhibitor spebrutinib: application to metabolic stability evaluation.
Abdelhameed AS; Attwa MW; Al-Shaklia NS; Kadi AA
R Soc Open Sci; 2019 Jun; 6(6):190434. PubMed ID: 31312501
[TBL] [Abstract][Full Text] [Related]
13. Validated LC-MS/MS assay for quantification of the newly approved tyrosine kinase inhibitor, dacomitinib, and application to investigating its metabolic stability.
Abdelhameed AS; Kadi AA; Attwa MW; AlRabiah H
PLoS One; 2019; 14(4):e0214598. PubMed ID: 30947315
[TBL] [Abstract][Full Text] [Related]
14. A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate.
Attwa MW; Kadi AA; Darwish HW; Amer SM; Alrabiah H
Eur J Mass Spectrom (Chichester); 2018 Aug; 24(4):344-351. PubMed ID: 29629565
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study.
AlRabiah H; Kadi AA; Attwa MW; Mostafa GAE
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Oct; 1154():122195. PubMed ID: 32943176
[TBL] [Abstract][Full Text] [Related]
16. Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry.
Darwish HW; Kadi AA; Attwa MW; Almutairi HS
Clin Chim Acta; 2018 May; 480():180-185. PubMed ID: 29458050
[TBL] [Abstract][Full Text] [Related]
17. Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.
Sparidans RW; Wang Y; Schinkel AH; Schellens JHM; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():167-172. PubMed ID: 30396050
[TBL] [Abstract][Full Text] [Related]
18. A simple liquid chromatography-tandem mass spectrometry method to accurately determine the novel third-generation EGFR-TKI naquotinib with its applicability to metabolic stability assessment.
Alrabiah H; Kadi AA; Attwa MW; Abdelhameed AS
RSC Adv; 2019 Feb; 9(9):4862-4869. PubMed ID: 35514667
[TBL] [Abstract][Full Text] [Related]
19. Rapid LC-MS/MS Bosutinib Quantification with Applications in Metabolic Stability Estimation.
Attwa MW; Alanazi MM
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838629
[TBL] [Abstract][Full Text] [Related]
20. Investigation of metabolic degradation of new ALK inhibitor: Entrectinib by LC-MS/MS.
Attwa MW; Darwish HW; Alhazmi HA; Kadi AA
Clin Chim Acta; 2018 Oct; 485():298-304. PubMed ID: 30006284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
